FTC Clears Bayer's Purchase of Conceptus

bayer logo conceptus acquisition
John MacDougal, AFP/Getty Images
NEW YORK -- The German drug company Bayer AG has received antitrust clearance from the Federal Trade Commission for its approximately $1.1 billion acquisition of Conceptus.

Bayer announced the deal last month, saying that it would help to expand the kinds of birth control it offers.

Mountain View, Calif.-based Conceptus Inc. (CPTS) makes Essure, an irreversible birth control method in which small metal and polyester coils are inserted to block a woman's fallopian tubes. The procedure can be done in 10 minutes in a doctor's office.

Bayer already markets birth control pills and intrauterine devices.

The transaction could be completed by midyear.


Increase your money and finance knowledge from home

Reading a Stock Quote

Learn to read the ingredients of a stock.

View Course »

Investor’s Toolbox

Improve your investing savvy with the right financial toolset.

View Course »

Add a Comment

*0 / 3000 Character Maximum